{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'administration as needed. Study patients should also receive antiviral prophylaxis for', 'herpetic viral infection beginning on Day 1 and continuing for a minimum of 1 month. If', 'diphenhydramine IV is not available, an equivalent H1 antagonist can be used at an', 'equivalent dosing, via IV route. If no H1 antagonist is available in IV formulation, an oral', 'formulation of an equivalent compound can be used at an equivalent dosing, 2 hours prior', 'to infusion.', 'Vital signs during infusion days will be monitored.', 'AE/SAE will be monitored (if any).', 'Concomitant medication will be checked and reported (if any).', 'The following infusion management procedures must be utilized for each infusion and each', 'treatment course:', '-', 'Pre-infusion :', 'Physicians should obtain a baseline ECG and vital signs (including heart rate and blood', 'pressure measurement), screen for pre-existing hemorrhagic, cardiovascular (including', 'venous thromboembolism) and cerebrovascular risk factors, screen for lung disease, review', 'concomitant medications (eg, antiplatelet agents, anticoagulants), perform laboratory tests', '(complete blood count with differential, serum transaminases, serum creatinine, test of', 'thyroid function and urinalysis with microscopy), and evaluate infusion-related risks.', 'Physician should also apply the following contraindications when treating patients in this', 'study:', 'Hypersensitivity to the active substance, or to any of the excipients', 'Human Immunodeficiency Virus (HIV) infection', 'Severe active infection', 'Uncontrolled hypertension', 'History of arterial dissection of the cervicocephalic arteries', 'History of stroke', 'History of angina pectoris or myocardial infarction', 'Known coagulopathy or on concomitant anti-coagulant therapy', \"It is at investigator's discretion to treat or not treat patient with alemtuzumab after clinical\", 'evaluation.', '-', 'During infusion: Continuous/frequent monitoring of heart rate, blood pressure assessment (at', 'least hourly) and overall clinical status of the patients including consideration of the volume', 'of fluids administered. The following are recommendations in case of clinical', 'abnormities/severe adverse event:', 'Interrupt infusion', 'Medically evaluate the patient guided by the adverse event profile of alemtuzumab', 'prior to considering restarting therapy', 'Provide appropriate treatment as needed', 'Consider permanently discontinuing the alemtuzumab infusion if the patient shows', 'clinical symptoms suggesting development of a serious adverse event associated', 'Property of the Sanofi Group - strictly confidential', 'Page 71', 'VV-CLIN-02544065.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'with the infusion (myocardial ischemia, hemorrhagic stroke, cervico-cephalic arterial', 'dissection or pulmonary alveolar hemorrhage).', 'Implement appropriate measures for patients at risk of venous thromboembolism:', 'repeated ambulation during infusion and/or compression stockings.', '-', 'Post-infusion: Observation and education of patients', 'Observation for infusion reactions is recommended for a minimum of 2 hours after', 'alemtuzumab infusion; 2 hours after infusion, patients should be cautious and', 'reporting if any of the infusion reactions develop within 48 hours.', 'Patients with clinical symptoms suggesting development of a serious adverse event', 'temporarily associated with the infusion (myocardial ischemia, hemorrhagic stroke,', 'cervico-cephalic arterial dissection or pulmonary alveolar hemorrhage) should be', 'closely monitored until complete resolution of the symptoms. The observation time', 'should be extended as appropriate.', 'Patients with persistent blood pressure elevation should be referred to an appropriate', 'medical facility for continued monitoring and treatment.', 'The patients should be educated on the potential for delayed onset of infusion', 'associated reactions and symptoms and signs of cardiovascular or cerebrovascular', 'events, and instructed to report symptoms and/or seek appropriate medical care.', 'Perform MRI scan without contrast.', 'Perform EDSS assessment.', 'Perform SDMT and BVMT-R test.', 'Recording of PedsQL/Ped NeuroQoL.', '10.1.11 Visit 17 to Visit 18/M13 to M14', 'The following assessments should be done as listed in the study flow chart:', 'AE/SAE will be monitored (if any).', 'Concomitant medication (if any) will be checked at Visit 17 and Visit 18.', 'Blood samples collection for hematology, ALT, serum creatinine, and urinalysis.', 'Blood samples collection for lymphocyte phenotyping and for ADA at Visit 17 only.', 'Blood samples collection for PK.', '10.1.12 Visit 19/M15', 'The following assessments should be done as listed in the study flow chart:', 'AE/SAE will be monitored (if any).', 'Concomitant medication will be checked and reported (if any).', 'Property of the Sanofi Group - strictly confidential', 'Page 72', 'VV-CLIN-02544065 5.0']\n\n###\n\n", "completion": "END"}